Smallpox treatment, TPOXX, receives FDA approval

SIGA Technologies, Inc. (SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that the U.S. Food and Drug Administration (FDA) has approved oral TPOXX(R) (tecovirimat) for the treatment of smallpox to mitigate the impact of a potential outbreak. TPOXX, a small-molecule antiviral treatment for smallpox, is the first therapy specifically approved for ["]

The post Smallpox treatment, TPOXX, receives FDA approval appeared first on Outbreak News Today.